The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

Summary: Abemaciclib, an inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), has recently been approved for the treatment of hormone receptor-positive breast cancer. In this study, we use murine syngeneic tumor models and in vitro assays to investigate the impact of abemaciclib on T cells, the tumor immune microenvironment and the ability to combine with anti-PD-L1 blockade. Abemaciclib monotherapy resulted in tumor growth delay that was associated with an increased T cell inflammatory signature in tumors. Combination with anti-PD-L1 therapy led to complete tumor regressions and immunological memory, accompanied by enhanced antigen presentation, a T cell inflamed phenotype, and enhanced cell cycle control. In vitro, treatment with abemaciclib resulted in increased activation of human T cells and upregulated expression of antigen presentation genes in MCF-7 breast cancer cells. These data collectively support the clinical investigation of the combination of abemaciclib with agents such as anti-PD-L1 that modulate T cell anti-tumor immunity.: Schaer, Beckmann et al. describe unique immune-modulating properties of abemaciclib that include upregulation of antigen presentation on tumor cells and increased T cell activation. These activities synergize with anti-PD-L1 therapy to further enhance immune activation, including macrophage and DC antigen presentation, and also lead to a reciprocal increase in abemaciclib-dependent cell cycle gene regulation. Keywords: CDK4/6, abemaciclib, PD-1, PD-L1, combination immunotherapy, cancer

Abstract licence: CC BY-NC

• Immunotherapy in Breast Cancer · 2024

• Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials · 2022

• Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer · 2022

• Combination strategies with PD-1/PD-L1 blockade: current advances and future directions · 2022

• CDK4/6 inhibitors induce replication stress to cause long‐term cell cycle withdrawal · 2022

• Turning cold tumors into hot tumors by improving T-cell infiltration · 2021

• Molecular determinants of response to PD-L1 blockade across tumor types · 2021

• The Immunology of Hormone Receptor Positive Breast Cancer · 2021

• The application and prospect of CDK4/6 inhibitors in malignant solid tumors · 2020

• Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors · 2020

• CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner · 2020

• DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load · 2019

• MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer · 2019

• PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review · 2019

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.